Trial Profile
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Cabergoline (Primary)
- Indications Adenoma; Pituitary cancer
- Focus Therapeutic Use
- 19 Jan 2023 Planned End Date changed from 1 May 2026 to 1 Dec 2027.
- 19 Jan 2023 Planned primary completion date changed from 1 May 2022 to 1 Dec 2025.
- 31 Aug 2021 Planned End Date changed from 1 May 2025 to 1 May 2026.